Ohio Doctor Loses Controlled-Drug Authority After Ignoring DEA Notices
Published Date: 11/19/2026
Notice
Summary
Dr. Dave Allen Wright from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in Ohio and didn’t respond to the DEA’s notices. Since he didn’t ask for a hearing, the DEA officially revoked his registration, meaning he can’t legally prescribe or manage controlled drugs anymore. This decision is final as of November 2026 and affects Dr. Wright’s ability to work with controlled substances.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked — Controlled Drugs
Dr. Dave Allen Wright's DEA Certificate of Registration No. BW4012720 is revoked, so he may not legally prescribe, administer, dispense, or otherwise handle controlled substances in Ohio. The Order finds his Ohio medical license expired on October 1, 2025, and the revocation is effective December 21, 2026.
Renewal and New-Registration Applications Denied
The Order also denies any pending applications by Dave Allen Wright to renew or modify Certificate No. BW4012720 and denies any other pending application for additional DEA registration in Ohio. This denial is issued along with the revocation and takes effect as stated in the Order.
15-Day Window to Seek Reconsideration
The Order states that the registrant may dispute the Agency's finding by filing a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of the Order. Any motion and response must be filed and served by email to the other party and to the Office of the Administrator, Drug Enforcement Administration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-23513, Kyndahl D. Bertram, D.O.; Decision and Order
Dr. Kyndahl D. Bertram lost her DEA registration because she no longer has permission to handle controlled substances in Virginia. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on July 31, 2026. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-23006, Importer of Controlled Substances Application: NSI Lab Solutions LLC
NSI Lab Solutions LLC wants to become an official importer of certain controlled substances, like Amineptine and Mesocarb. People who make or use these drugs can share their thoughts or ask for a hearing by December 14, 2026. This move could affect companies handling these substances and involves a formal review process with no immediate cost changes announced.
Previous / Next Documents
Previous: 2026-23527, Sunshine Act Meetings
The Legal Services Corporation Board will hold an open virtual meeting on November 23, 2026, starting at 11:30 a.m. ET. They'll discuss the Inspector General’s report and related actions, with all materials available online a day before. This keeps the public in the loop without any cost changes or delays.
Next: 2026-23512, Advisory Committee on Historical Diplomatic Documentation-Notice of Closed and Open Meeting in December 2026
The Advisory Committee on Historical Diplomatic Documentation will meet on December 15, 2026, with an open online session for the public and a closed session to discuss secret government record decisions. This affects anyone interested in U.S. diplomatic history and how records get shared or kept classified. If you want to join the open meeting, RSVP by December 8—no cost involved, just your curiosity!